Navigation Links
Oclaro Announces Second Quarter Fiscal Year 2013 Financial Results
Date:1/31/2013

SAN JOSE, Calif., Jan. 31, 2013 /PRNewswire/ -- Oclaro, Inc. (NASDAQ: OCLR), a provider of optical components, modules and subsystems, today announced the financial results for its second quarter of fiscal year 2013, which ended December 29, 2012.

"Our financial results for the second quarter of fiscal 2013 demonstrate the progress we are making after the merger," said Alain Couder, chairman and CEO. "Our revenues were at the top-end of guidance and we have successfully executed to the planned synergies on schedule. We also took action to strengthen our balance sheet.  Looking ahead, market and economic conditions remain uncertain in a typically softer March quarter. As a result, our efforts will remain focused on reducing operating expenses and improving margin, as well as capitalizing on our new product introductions and strong customer relationships to maximize revenues."

Results for the Second Quarter of Fiscal 2013:Oclaro closed its merger with Opnext, Inc. on July 23, 2012. The financial results for the second quarter of fiscal 2013 include a full quarter of operating results of Opnext. The financial results for the first quarter of fiscal 2013 include approximately ten weeks of operating results of Opnext since the closing of the merger. Results for the second quarter of fiscal 2012 were pre-merger Oclaro and do not include the operating results of Opnext.

  • Revenues were $159.5 million for the second quarter of fiscal 2013, compared with revenues of $148.8 million in the first quarter of fiscal 2013. Pro forma combined revenues for the first quarter of fiscal 2013, including Opnext for the full quarter, were $160.2 million.
  • GAAP gross margin was 13% for the second quarter of fiscal 2013, compared with a GAAP gross margin of 12% in the first quarter of fiscal 2013.
  • Non-GAAP gross margin was 15% for the second quarter of fisca
    '/>"/>

  • SOURCE Oclaro, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. Oclaro Announces Fourth Quarter and Fiscal Year 2012 Financial Results
    2. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
    3. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
    4. Blue Belt Technologies Announces First U.S. Sale of NavioPFS Surgical System
    5. IDEV Announces Results from Revascularization with Supera on Real World Patients (RESTORE) Study, Demonstrating Positive Clinical Outcomes in Significantly Diseased Patients with Long Lesions
    6. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
    7. Targovax AS Announces First Patient Included in Phase I/II Clinical Study With the Therapeutic Cancer Vaccine TG01 in Operable Pancreatic Cancer
    8. Kemwell Announces Successful Pre-NDA US FDA Inspection
    9. Cell Therapeutics Announces Data Safety and Monitoring Board Recommendation to Continue the GOG-0212 Phase 3 Clinical Trial of OPAXIOTM as Maintenance Therapy in Ovarian Cancer
    10. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
    11. Vanish Announces Tattoo Removal Giveaway for Valentines Day
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014 As health officials across the ... select Meijer pharmacies in Michigan will ... eligible patients, enabling Meijer pharmacists to administer tests and, in ... by a physician participating in the study. The ...
    (Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
    (Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014  Humberto ... in Dermatology Achievement Award" from the Journal of ... Dermatology Aesthetic & Clinical Conference (ODAC). The event is January ... Florida . The ...
    Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
    ... 2010 Renal Advantage and Liberty Dialysis, which last month ... dialysis services in the U.S., today announced that they have ... not disclosed – was completed on December 17, 2010.  The ... in 260 locations in 32 states. "The completion ...
    ... 22, 2010 Particle Sciences Inc. (PSI), a leading ... that, when coupled with an antigen, enhanced its immunogenicity, ... work is described in Vaccine , 2010 Dec. ... strong systemic and mucosal cellular and humoral immune responses ...
    Cached Medicine Technology:Renal Advantage and Liberty Dialysis Deal Completed 2Renal Advantage and Liberty Dialysis Deal Completed 3Particle Sciences Develops Wax Nanoparticles that Enhance Immune Response to Antigens 2
    (Date:4/17/2014)... Boston University School of Medicine (BUSM) have discovered ... in an experimental model. The findings, reported in ... Abuse , may lead to more effective treatments ... one of the leading causes of illness and ... economic impact by limiting the productivity of workers ...
    (Date:4/17/2014)... team led by researchers at UC Davis has shown ... key role in cell division, also boosts the mitochondrial ... time the complex has been shown to perform both ... excellent target to control cellular energy production, potentially advancing ... online today in the journal Developmental Cell . ...
    (Date:4/17/2014)... led by Cesar A. Arias, M.D., Ph.D., at The ... has identified a new superbug that caused a bloodstream ... the April 17 issue of The New England ... part of a class of highly-resistant bacteria known as ... a major cause of hospital and community-associated infections. The ...
    (Date:4/17/2014)... uncommon these days to find a colored ribbon representing a ... cancer. But what color ribbon does one think of with ... color, for many suffering from the disease, black may be ... study consisting of lung cancer patients, primarily smokers between the ... light on the stigma often felt by these patients, the ...
    (Date:4/17/2014)... alleviates muscle soreness after exercise, according to a ... at Chicago. , The study, reported online in ... Physical Medicine and Rehabilitation , also showed that ... not exercised, suggesting that massage has benefits for ... , Improved circulation and relief of muscle soreness ...
    Breaking Medicine News(10 mins):Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:Massage therapy improves circulation, eases muscle soreness 2
    ... investments in nanoscale science and engineering will create revolutions ... treatment, and space travel. The hope is that many ... nanotechnology enabled products. While new technologies often do ... other social problems or create entirely new ones. The ...
    ... Reporter , THURSDAY, Nov. 18 (HealthDay News) -- Patients in ... because of cost than residents of other developed countries, a ... industrialized countries, the United States also has the highest out-of-pocket ... "The 2010 survey findings point to glaring gaps in ...
    ... into mice with metastatic melanoma has resulted in permanent ... cancer, according to an article to be published in ... Clinical Investigation . The online version is now available. ... modified lentivirus to introduce a potent anti-melanoma T cell ...
    ... nice extra, not a strategic imperative. But the data demonstrate ... L. Berry of Texas A&M University, Ann M. Mirabito of ... Texas MD Anderson Cancer Center. Their research shows that ... is impressive sometimes as high as six to one. ...
    ... WASHINGTON, Nov. 18, 2010 The latest episode in ... Global Challenges/Chemistry Solutions ," focuses on development and successful ... kills up to 98 percent of disease-causing bacteria in ... technology could aid many of the almost one billion ...
    ... Ill. -- Taking time off from certain osteoporosis drugs may ... at Loyola University Health System. Researchers found that bone density ... drug holiday from bisphosphonates, a popular class of osteoporosis drugs ... decay in the jaw bone. "These drugs are potentially ...
    Cached Medicine News:Health News:Nanotechnology and equity issues explored in new book 2Health News:On Health Policies, U.S. Lags Other Nations: Survey 2Health News:On Health Policies, U.S. Lags Other Nations: Survey 3Health News:On Health Policies, U.S. Lags Other Nations: Survey 4Health News:Gene therapy for metastatic melanoma in mice produces complete remission 2Health News:Wellness programs provide high returns, research reveals 2Health News:Taking a break from osteoporosis drugs can protect bones 2
    ... The PK Super-Sect is a ... tissue removal with minimal thermal spread ... for superior hemostatis. It can be ... gland and/or bladder tumor. It is ...
    ... CS is a fully ... treatment system designed to ... unlimited flexibility. Cryocare CS ... specific physician needs through ...
    ... Oncura's SeedNet system is a minimally invasive ... to learn and simple to use, SeedNet ... the cryoablation process. SeedNet is the ... Ultra-thin needles, exclusive to the SeedNet system, ...
    Medium Clip Appliers. American-made stainless steel, 6" long, curved tip. For use with VE-6-25 and VE-6-10 titanium surgical clips only....
    Medicine Products: